@article{f5b76ed638f14fe7bad645a6de03d02a,
title = "Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to Know",
keywords = "Endoradiotherapy, PRLT, Prostate cancer, Radioligand therapy, Theranostics",
author = "Rowe, {Steven P.} and Sadaghiani, {Mohammad S.} and Andrei Gafita and Sara Sheikhbahaei and Pomper, {Martin G.} and Jeffrey Young and Avery Spitz and Werner, {Rudolf A.} and Oldan, {Jorge D.} and Solnes, {Lilja B.}",
note = "Funding Information: M.G. Pomper is a coinventor on a US patent covering 18F-DCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. S.P. Rowe is a consultant for Progenics Pharmaceuticals Inc., United States, a wholly owned subsidiary of Lantheus Pharmaceuticals, Inc. and the licensee of 18F-DCFPyL. M.G. Pomper and S.P. Rowe have received research funding from Progenics Pharmaceuticals. All other authors declare that there is no relevant conflict of interest.",
year = "2024",
month = jan,
doi = "10.1016/j.rcl.2023.07.003",
language = "English (US)",
volume = "62",
pages = "177--187",
journal = "Radiologic clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "1",
}